Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

UroGen Pharma (URGN) EBITDA (2016 - 2025)

Historic EBITDA for UroGen Pharma (URGN) over the last 10 years, with Q3 2025 value amounting to -$33.3 million.

  • UroGen Pharma's EBITDA fell 4239.94% to -$33.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$164.9 million, marking a year-over-year decrease of 4334.22%. This contributed to the annual value of -$126.8 million for FY2024, which is 2419.09% down from last year.
  • Per UroGen Pharma's latest filing, its EBITDA stood at -$33.3 million for Q3 2025, which was down 4239.94% from -$49.9 million recorded in Q2 2025.
  • UroGen Pharma's 5-year EBITDA high stood at -$21.9 million for Q3 2023, and its period low was -$49.9 million during Q2 2025.
  • Over the past 5 years, UroGen Pharma's median EBITDA value was -$28.5 million (recorded in 2021), while the average stood at -$30.4 million.
  • As far as peak fluctuations go, UroGen Pharma's EBITDA soared by 1570.0% in 2023, and later tumbled by 4955.83% in 2025.
  • UroGen Pharma's EBITDA (Quarter) stood at -$28.5 million in 2021, then decreased by 1.19% to -$28.8 million in 2022, then rose by 10.24% to -$25.9 million in 2023, then crashed by 45.7% to -$37.7 million in 2024, then grew by 11.57% to -$33.3 million in 2025.
  • Its last three reported values are -$33.3 million in Q3 2025, -$49.9 million for Q2 2025, and -$43.9 million during Q1 2025.